73 related articles for article (PubMed ID: 18948752)
1. Fbxw7 in cell cycle exit and stem cell maintenance: insight from gene-targeted mice.
Onoyama I; Nakayama KI
Cell Cycle; 2008 Nov; 7(21):3307-13. PubMed ID: 18948752
[TBL] [Abstract][Full Text] [Related]
2. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
[TBL] [Abstract][Full Text] [Related]
3. A FBXO7/EYA2-SCF
Shen JZ; Qiu Z; Wu Q; Zhang G; Harris R; Sun D; Rantala J; Barshop WD; Zhao L; Lv D; Won KA; Wohlschlegel J; Sangfelt O; Laman H; Rich JN; Spruck C
Mol Cell; 2022 Mar; 82(6):1123-1139.e8. PubMed ID: 35182481
[TBL] [Abstract][Full Text] [Related]
4. Targeted variant prevalence of FBXW7 gene mutation in colorectal carcinoma propagation. The first systematic review and meta-analysis.
Afolabi HA; Salleh SM; Zakaria Z; Seng CE; Nafi NM; Bin AbdulAziz AA; Wada Y; Irekeola AA; Al-Ml-Hanna SB; Mussa A
Heliyon; 2024 Jun; 10(11):e31471. PubMed ID: 38845996
[TBL] [Abstract][Full Text] [Related]
5. Retraction Notice to: A FBXO7/EYA2-SCF
Shen JZ; Qiu Z; Wu Q; Zhang G; Harris R; Sun D; Rantala J; Barshop WD; Zhao L; Lv D; Won KA; Wohlschlegel J; Sangfelt O; Laman H; Rich JN; Spruck C
Mol Cell; 2024 May; ():. PubMed ID: 38823387
[No Abstract] [Full Text] [Related]
6. FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies.
Wang W; Jiang K; Liu X; Li J; Zhou W; Wang C; Cui J; Liang T
Front Pharmacol; 2023; 14():1278056. PubMed ID: 38027013
[TBL] [Abstract][Full Text] [Related]
7. The significance of CDT1 expression in non-cancerous and cancerous liver in cases with hepatocellular carcinoma.
Ogawa M; Moriyama M; Midorikawa Y; Nakamura H; Shibata T; Kuroda K; Nakayama H; Kanemaru K; Miki T; Sugitani M; Takayama T
J Clin Biochem Nutr; 2023 Nov; 73(3):234-248. PubMed ID: 37970553
[TBL] [Abstract][Full Text] [Related]
8. The genomic regulation of metastatic dormancy.
Gelman IH
Cancer Metastasis Rev; 2023 Mar; 42(1):255-276. PubMed ID: 36600151
[TBL] [Abstract][Full Text] [Related]
9. FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies.
Shen W; Zhou Q; Peng C; Li J; Yuan Q; Zhu H; Zhao M; Jiang X; Liu W; Ren C
Front Oncol; 2022; 12():880077. PubMed ID: 35515121
[TBL] [Abstract][Full Text] [Related]
10. The Krüppel-like factor Cabut has cell cycle regulatory properties similar to E2F1.
Zhang P; Katzaroff AJ; Buttitta LA; Ma Y; Jiang H; Nickerson DW; Øvrebø JI; Edgar BA
Proc Natl Acad Sci U S A; 2021 Feb; 118(7):. PubMed ID: 33558234
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of WNT7A-β-catenin signaling pathway sensitizes oral squamous cell carcinoma to cisplatin.
Tian J; Cui X; Feng Y; Gu L
Int J Clin Exp Pathol; 2018; 11(10):4926-4933. PubMed ID: 31949568
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Metastatic Tumor Dormancy and Implications for Cancer Therapy.
Neophytou CM; Kyriakou TC; Papageorgis P
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31817646
[TBL] [Abstract][Full Text] [Related]
13. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
[TBL] [Abstract][Full Text] [Related]
14. Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy.
Ishii N; Araki K; Yokobori T; Watanabe A; Tsukagoshi M; Kubo N; Suzuki H; Saito F; Altan B; Hosouchi Y; Shirabe K; Kuwano H
Oncol Lett; 2017 May; 13(5):3653-3661. PubMed ID: 28521468
[TBL] [Abstract][Full Text] [Related]
15. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors.
Kitade S; Onoyama I; Kobayashi H; Yagi H; Yoshida S; Kato M; Tsunematsu R; Asanoma K; Sonoda K; Wake N; Hata K; Nakayama KI; Kato K
Cancer Sci; 2016 Oct; 107(10):1399-1405. PubMed ID: 27486687
[TBL] [Abstract][Full Text] [Related]
16. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
[TBL] [Abstract][Full Text] [Related]
17. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
[TBL] [Abstract][Full Text] [Related]
18. MERIT40 deficiency expands hematopoietic stem cell pools by regulating thrombopoietin receptor signaling.
Rozenova K; Jiang J; Donaghy R; Aressy B; Greenberg RA; Tong W
Blood; 2015 Mar; 125(11):1730-8. PubMed ID: 25636339
[TBL] [Abstract][Full Text] [Related]
19. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer.
Calcagno DQ; Freitas VM; Leal MF; de Souza CR; Demachki S; Montenegro R; Assumpção PP; Khayat AS; Smith Mde A; dos Santos AK; Burbano RR
BMC Gastroenterol; 2013 Sep; 13():141. PubMed ID: 24053468
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
